

CLINICAL EXAMPLES OF WOUND HEALING FOLLOWING DESTRUCTION OF TUMOURS IN DOMESTIC ANIMALS TREATED WITH TIGILANOL TIGLATE

OBJECTIVES

To provide examples of enhanced wound healing observed in domesticated animals following tumour ablation by tigilanol tiglate.

MATERIALS & METHODS

- **Animals:**
 - Dogs, cats, and horses with tumours unsuitable for current standard of care.
- **Treatment:**
 - Depending on tumour volume, tigilanol tiglate doses (0.5–2.0 mg) were delivered as single treatments, involving multiple injections into tumours and their surroundings.

RESULTS

- Localised inflammation and tumour vasculature disruption were evident as erythema and bruising 2 hours post-treatment.
- Within 5–14 days post-injection, the necrotic remnants of the treated tumours sloughed, producing open wounds.
- With no active management or interventions (e.g., dressings, lotions, antibiotics, or other concomitant medications), wounds showed exceptional dermal healing responses, characterised by rapid granulation tissue development and enhanced re-epithelialisation.
- Resolved wounds also displayed other preferential healing responses, such as minimal tissue deficit, accelerated closure, minimal scarring, and hair regrowth.

CLINICAL INTEREST

Tigilanol tiglate promotes enhancement of healing responses, wound resolution, and cosmetic outcomes.



REFERENCES

Campbell, Miller, Blum, Toole, Ayerbe, Verning, Poulos, Boyle, Parsons, Moses, Steadman, Moseley, Schmidt, Gordon, Reddell. Exceptional in vitro wound healing following destruction of cutaneous and subcutaneous tumors in domesticated animals treated with the novel epoxy-tigliane drug EBC-46. Wound Rep Reg (2014) 22 A76.